EX-99.1 2 rdy0836_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 


Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

 

CIN: L85195TG1984PLC004507

 

Tel:       + 91 40 4900 2900

Fax:     + 91 40 4900 2999

Email: mail@drreddys.com

Web:   www.drreddys.com

 

January 1, 2026

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/Madam,

 

Ref:

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

 

This is to inform that the Company has received five separate orders from GST Authority towards tax demand including interest and levying penalty for the period FY 2018-19 to FY 2022-23. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:

 

S.No.

Name of the authority

:

Joint Commissioner, Office of Principal Commissioner of Central Tax, Visakhapatnam 

1

Nature and details of the action(s) taken, or order(s) passed

:

The Company has received such orders seeking demand including interest and levying penalty under APGST Act 2017. 

2 

Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority

:

Orders dated December 31, 2025, were received by the Company on December 31, 2025.

3

Details of the violation(s)/ contravention(s) committed or alleged to be committed

:

The authority has passed the orders on the ground that the Company has availed excess input tax credit. 

4

 

Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible

 

:

 

The above orders levy penalty as detailed below:

 

Financial Year

Penalty (INR)

FY 2018-19

1,89,30,110

FY 2019-20

80,41,186

FY 2020-21

3,52,95,063

FY 2021-22

1,45,04,023

FY 2022-23

70,86,675

 

Based on our evaluation, there is no material impact on the financials, operations, or other activities of the Company.

 

The Company will evaluate filing necessary appeal with the appellate authority in this regard.

 

This is for your information and records.

 

Thanking you,

 

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

 


 

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR